LVDD

HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients

Retrieved on: 
Tuesday, March 26, 2024
Diabetes, Disease, Echocardiography, HSCS, Congress, Algorithm, Intelligence, Anesthesia, Patient, Mortality, LVDD, Society, Anesthesiology, Type, Use, American Society of Echocardiography, Medical device

Preoperative left ventricular diastolic dysfunction (LVDD) is very common and one of the important causes of perioperative morbidity and mortality in cardiac and non-cardiac surgeries.

Key Points: 
  • Preoperative left ventricular diastolic dysfunction (LVDD) is very common and one of the important causes of perioperative morbidity and mortality in cardiac and non-cardiac surgeries.
  • In the study, patients undergoing preoperative anesthesia evaluation for cardiac and non-cardiac surgeries were enrolled.
  • For patients indicated for preoperative echocardiography, LVDD was diagnosed and graded as per American Society of Echocardiography (ASE) guidelines and a MyoVista wavECG was also performed.
  • Based on these findings, 25 of the 60 non-LVDD patients could be safely excluded from referral to preoperative echocardiography.

RWJBarnabas Health and Rutgers Health to Showcase Breakthrough Cardiology Data at the American College of Cardiology Scientific Session & Expo

Retrieved on: 
Monday, March 25, 2024
CMR, TME, FACC, National Health Interview Survey, Research, Obesity, Hypertension, MRI, Cooperman Barnabas Medical Center, Facial muscles, HIV, Diabetes, Risk, National Health, Patient, Stroke, RWJBarnabas Health, Community Medical Center, Mortality, Aortic stenosis, American College of Cardiology, Telehealth, Faculty, New Jersey Medical School, NHIS, Abstract, American College, Smoking, LVDD, Rutgers University, Division, TAVR, Collection, Jersey City Medical Center, ACC, YPLL, Acute coronary syndrome, Health, Meta-analysis, Dietary supplement

WEST ORANGE, N.J., March 25, 2024 /PRNewswire/ -- Physician-scientists from RWJBarnabas Health and Rutgers Health will present an extensive portfolio of innovative cardiovascular data from their clinical research program at the American College of Cardiology's (ACC) Annual Scientific Session & Expo in Atlanta, Georgia on April 6 to 8, 2024. A total of 59 abstracts have been accepted, composed of data evaluating and educating on risk factors, treatment options and ongoing research advances to improve cardiovascular care and outcomes for patients.

Key Points: 
  • A total of 59 abstracts have been accepted, composed of data evaluating and educating on risk factors, treatment options and ongoing research advances to improve cardiovascular care and outcomes for patients.
  • RWJBarnabas Health cardiac centers of excellence are nationally recognized for patient care and superior outcomes, including being named as one of Becker's top 100 Great Heart Programs in the country and recognized by American College of Cardiology as a Proven Quality Program.
  • Prior studies suggest that distinct patient subgroups with aortic stenosis may experience left ventricular systolic and diastolic dysfunction before the development of severe AS.
  • The study included patients who had received an angiogram done within 14 days of the CMR.

HeartSciences Announces Further Internationalization of its Patent Portfolio

Retrieved on: 
Friday, February 3, 2023
HSCS, AI, Korean Intellectual Property Office, Cardiovascular disease, CWT, Mathematics, Issues relating to social networking services, Intellectual property, Artificial intelligence, South Korean Patent Act, Patent, Heart, KIPO, Electrocardiography, LVDD, Death, ECG, 3D printing, Pharmaceutical industry

To date HeartSciences has been granted nine US patents and 30 international patents for a total of 39 granted patents.

Key Points: 
  • To date HeartSciences has been granted nine US patents and 30 international patents for a total of 39 granted patents.
  • The Company has nine additional patents pending across the US and international markets.
  • Andrew Simpson, Chief Executive Officer of HeartSciences, commented, “Millions of ECG’s are performed worldwide every week and the ECG is by far the most ubiquitous cardiac test.
  • This additional valuable information is used as part of the input in developing the AI models and helps improve overall model performance.

HeartSciences Provides Business Update and Reports First Quarter Fiscal 2023 Financial Results

Retrieved on: 
Tuesday, September 13, 2022
Wireless ambulatory ECG, FDA, HSCS, Company, Hypertension, Diabetes, U.S. Securities and Exchange Commission, Patient, Degenerative disease, IPO, Technology, Completeness, Cardiology, ECG, NASDAQ, LVDD, Heart, Research, Security (finance), GLOBE, Ischemia, Medical device

Southlake, Texas, Sept. 13, 2022 (GLOBE NEWSWIRE) --  Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to significantly expand and improve an ECG’s clinical usefulness by detecting cardiac dysfunction, today provided a business update and reported financial results for the fiscal first quarter ended July 31, 2022.Andrew Simpson, Chief Executive Officer of HeartSciences, commented, “We are nearing completion of patient recruitment for the FDA pivotal clinical validation study of the MyoVista® wavECG™ device with over 500 patients recruited out of an overall target of 550 patients.  We expect to report study results following its completion.  Assuming a successful outcome, we remain on track to resubmit for FDA De Novo clearance in the current fiscal year.”

Key Points: 
  • Assuming a successful outcome, we remain on track to resubmit for FDA De Novo clearance in the current fiscal year.
  • We are seeking to address one of the most significant needs in healthcare by making an ECG a far more valuable cardiac screening tool.
  • Furthermore, during the first quarter of fiscal 2023, we completed our initial public offering with gross proceeds of approximately $6.375 million.
  • As a development-stage company, there were no meaningful revenues for the first quarter of 2023.

HeartSciences to Participate and Showcase the MyoVista at the Inauguration Ceremony of the Center for Innovation at Rutgers Robert Wood Johnson University Hospital

Retrieved on: 
Monday, September 12, 2022
Rutgers Biomedical and Health Sciences, FDA, Center, HSCS, United States Joint Congressional Committee on Inaugural Ceremonies, Robert Wood Johnson University Hospital, Hypertension, Industry, Diabetes, Mayo Clinic Center for Innovation, Degenerative disease, CEO, Technology, Cardiology, ECG, Innovation Center station, Robotics, Artificial intelligence, NASDAQ, LVDD, Heart, GLOBE, Ischemia, Rutgers University, Innovation, Medical device, Pharmaceutical industry

The Center is designed to encourage a multidisciplinary approach where clinicians work with industry to investigate and apply new technologies, to solve medical problems.

Key Points: 
  • The Center is designed to encourage a multidisciplinary approach where clinicians work with industry to investigate and apply new technologies, to solve medical problems.
  • We are currently working with the Rutgers Health network, which includes the Robert Wood Johnson University Hospital, as part of our FDA pivotal validation study and applaud their commitment to the latest technologies.
  • We are excited to participate in the celebration of this Innovation Center and showcase the MyoVista, as we continue to strengthen our relationship with Rutgers, stated Mr. Andrew Simpson, CEO of HeartSciences.
  • Robert Wood Johnson University Hospital is one of the institutions participating in HeartSciences pivotal study related to FDA submission.